Comparison of outcomes after percutaneous coronary intervention among different coronary subsets (stable and unstable angina pectoris and ST-segment and non-ST-segment myocardial infarction).
Percutaneous coronary intervention in the setting of acute myocardial infarction is known to predict stent thrombosis (ST). This study aims to compare the ST rates across different coronary subsets. This was an observational cohort study from a large, single-center registry. Included were 12,198 consecutive patients who underwent percutaneous coronary intervention with stenting. Patients were categorized according to their clinical presentation: stable angina pectoris (SAP, n = 3,700), unstable angina pectoris (UAP, n = 2,845), non-ST-segment elevation myocardial infarction (NSTEMI, n = 4,083), and ST-segment elevation myocardial infarction (STEMI, n = 1,570). The study end points were ST rates at 1 year. Patients with STEMI were younger with a lower prevalence of cardiovascular risk factors, except for smoking. More type C lesions were treated in STEMI, whereas drug-eluting stents were used less frequently in patients with STEMI compared with the other groups. Definite ST at 1 year was highest in patients with STEMI (1.4%; vs SAP, 0.4%; UAP, 0.5%; NSTEMI, 0.5%; p <0.001). One-year definite/probable ST rates were SAP, 0.8%; UAP, 1.1%; NSTEMI, 1.4%; and STEMI, 3.2% (p <0.001). On multivariable analysis, STEMI independently predicts definite ST (hazards ratio [HR] 3.07, 95% confidence interval [CI] 1.32 to 7.10), whereas both STEMI (HR 3.36, 95% CI 1.84 to 6.12) and NSTEMI (HR 2.04, 95% CI 1.20 to 3.07) were independent predictors of definite/probable ST. Clopidogrel cessation was the strongest predictor of ST (definite ST, HR 17.00, 95% CI 7.54 to 38.31; definite/probable ST, HR 4.69, 95% CI 2.39 to 9.20). In conclusion, in patients who underwent percutaneous coronary intervention, the acuity of clinical presentation corresponds to an increase in ST incidence. Adherence to clopidogrel is critical to prevent ST in patients who underwent percutaneous coronary intervention, especially in STEMI.
Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC.
Joshua P
JP
Loh
Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC.
Lakshmana K
LK
Pendyala
Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC.
Hironori
H
Kitabata
Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC.
Rebecca
R
Torguson
Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC.
Alfazir
A
Omar
Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC.
Sa'ar
S
Minha
Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC.
Fang
F
Chen
Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC.
Lowell F
LF
Satler
Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC.
Augusto D
AD
Pichard
Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC. Electronic address: ron.waksman@medstar.net.
Ron
R
Waksman
D000368:Aged; D060050:Angina, Stable / Q000175:diagnosis / Q000503:physiopathology / Q000601:surgery*; D000789:Angina, Unstable / Q000175:diagnosis / Q000503:physiopathology / Q000601:surgery*; D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000175:diagnosis / Q000453:epidemiology; D004219:District of Columbia / Q000453:epidemiology; D004562:Electrocardiography; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000175:diagnosis / Q000503:physiopathology / Q000601:surgery*; D062645:Percutaneous Coronary Intervention / Q000379:methods*; D011184:Postoperative Period; D015995:Prevalence; D011379:Prognosis; D012042:Registries; D012189:Retrospective Studies; D012307:Risk Factors; D015607:Stents; D013997:Time Factors